Captrust Financial Advisors Collegium Pharmaceutical, Inc Transaction History

Captrust Financial Advisors

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$21.16 - $30.8 $260,670 - $379,425	-12,319 Reduced 40.32%	18,234 $561,000
Q3 2023 Nov 14, 2023	SELL	$21.23 - $24.28 $313,652 - $358,712	-14,774 Reduced 32.59%	30,553 $682,000
Q2 2023 Aug 14, 2023	BUY	$21.06 - $24.0 $954,586 - $1.09 Million	45,327 New	45,327 $974,000
Q2 2022 Aug 16, 2022	SELL	$14.22 - $20.88 $17,490 - $25,682	-1,230 Reduced 57.18%	921 $16,000
Q1 2022 May 16, 2022	BUY	$17.2 - $22.5 $18,266 - $23,895	1,062 Added 97.52%	2,151 $44,000
Q4 2021 Feb 14, 2022	SELL	$17.5 - $21.35 $577 - $704	-33 Reduced 2.94%	1,089 $20,000
Q3 2021 Nov 16, 2021	SELL	$17.75 - $25.39 $1,295 - $1,853	-73 Reduced 6.11%	1,122 $22,000
Q2 2021 Aug 16, 2021	BUY	$21.74 - $25.28 $1,587 - $1,845	73 Added 6.51%	1,195 $28,000
Q1 2021 May 17, 2021	BUY	$19.25 - $26.1 $21,598 - $29,284	1,122 New	1,122 $27,000

249

36.2M

100K

21.1K

Ticker COLL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 34,126,200
Market Cap $1.11B
Description
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ...

Get notified when there are updates to the investment portfolio of Captrust Financial Advisors, based on Form 13F filings with the SEC.

Stay updated on Captrust Financial Advisors with notifications on news.